Kadmon Holdings operates as a biopharmaceutical firm, focusing on the discovery, development, and commercialization of small molecule compounds and biologics, primarily to address inflammatory and fibrotic disorders. Its leading therapeutic asset is KD025, an orally administered selective inhibitor of rho-associated coiled-coil kinase 2 (ROCK2), which is currently undergoing Phase II clinical evaluation for chronic graft-versus-host disease and various fibrotic conditions. Another key oral ROCK inhibitor, KD045, is also in development for fibrotic diseases. Additionally, the company is advancing KD033, an anti-PD-L1/IL-15 fusion protein, for oncological applications. Kadmon's broader pipeline encompasses Tesevatinib for autosomal dominant polycystic kidney disease; ribavirin, a nucleoside inhibitor, targeting hepatitis; and CLOVIQUE (trientine hydrochloride capsules) for the management of Wilson's disease. The company has established strategic partnerships and licensing agreements with entities like Nano Terra, Inc. and Dyax Corp. Established in 2010, Kadmon Holdings, Inc. maintains its headquarters in New York, New York.


Net sales
Gross margin
Net income